CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 113 enrolled
Drug / intervention
Fluviral®biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01626820
NCT01626820Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in Adults Aged 18 Years and Older

GlaxoSmithKline·interventional·Posted Jun 25, 2012·Updated Sep 7, 2018

In Brief

A Phase 3 clinical trial evaluating Fluviral® for Influenza. Completed, enrolled 113 participants across 1 site.

Detailed Summary

This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza strains recommended for the 2012-2013 season.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2012
Enrollment StartJul 19, 2012
Primary CompletionAug 10, 2012
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 14.0 years ago

Interventions

Fluviral®biological

1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0